JPRN-UMIN000027129招募中未知
Effect of docetaxel, estramustine and carboplatin chemotherapy on castration-resistant prostate cancer - DEC
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 85years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1 Patients who can not visit our hospitall 2 History of allergy on DEC agents 3 Patiens whom the doctor don't think appropriate
研究者
相似试验
已完成
2 期
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the ProstateProstate CancerNCT00083005National Institutes of Health Clinical Center (CC)60
招募中
2 期
Phase II study of Docetaxel, Cisplatin and S1 followed by surgery in advanced gastric cancer with lymph node metastasis of the paraaortagastric cancer with para-aortic lymph node metastasisJPRN-UMIN000006036Digestive Disease Support Organization (DDSO)30
招募中
不适用
A randomised clinical trial of docetaxel and estrogen in patients with castration resistant prostate cancerCastration-resistant prostate cancerJPRN-UMIN000006120Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences80
进行中（未招募）
1 期
Ebastine in combination with docetaxel as a treatment for castration-resistant metastatic prostate cancerMale patients with metastatic castration resistant prostate cancerMedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004259-35-DKRigshospitalet30
终止
3 期
Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate CancerProstatic NeoplasmsNCT00705822Sanofi54